ENCORE CAPITAL GROUP, INC. (ECPG): what the price requires

The current priced-in claim for ENCORE CAPITAL GROUP, INC. (ECPG) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ECPG

Headline

FieldValue
TickerECPG
CompanyENCORE CAPITAL GROUP, INC.
Current price$91.07/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed64.4%
Operating margin today36.0%
Margin expansion implied+28.4pp
Multiple paid3x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 10.2% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.72σ
cohort percentile (of 16 peers)6
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.63x5justifies
Earnings0.50x3justifies
Relative0.42x4justifies
Growth0.46x2justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.0%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
DCF Exit MultipleGrowth$301.860.30xyesExit EV/EBITDA: 5.2x / 8.2x / 11.2x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$191.160.48xyesP/E 12x (static sector reference · 2026-04), scenarios: 9.6x / 12.0x / 14.4x (bear / base = reference held flat / bull), EV/EBITDA N/Ax
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$143.510.63xyesBV/sh $46.36, ROE (TTM) 28.6%, ke 9.3%
Two-Stage Excess ReturnAsset$258.460.35xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$149.480.61xyesRev $1.9B, growth 30% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$154.080.59xyesEPS $12.84, growth 1% (input: historical EPS growth), PEG=5.80 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$181.940.50xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.39B × (1−23%) / WACC 4.0% → EPV (no growth)
Residual IncomeAsset$217.220.42xyesBV $46.36 + 5yr PV of (ROE (TTM) 28.6% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$115.730.79xyes√(22.5 × EPS $12.84 × BVPS $46.36) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarnings$0.019107.00xyesFCF $166.1M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.019107.00xyesSBC-adj FCF $0.15B (FCF $0.17B − SBC $0.02B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$414.300.22xyesEPS $12.84 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$33.762.70xyesBV $46.36 × (ROIC 2.9% / WACC 4.0%)
P/Sales SectorRelative$248.850.37xyesRevenue $1.85B × sector P/S 3.0x
PEG Fair ValueRelative$481.500.19xyesEPS $12.84 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$138.810.66xyesEPS $12.84 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$3.8b
Net debt / NOPAT (after-tax)7.74x
Net debt / operating income (pre-tax)5.97x
Interest coverage2.2x
Share count CAGR (buyback)-5.1%
Burning cashno

Bullet Takeaways

Encore trades around $82.97, roughly 6.5x trailing EPS of $12.84 and about 3x company-wide operating income, a multiple so low the price sits below what even a 5% annual profit decline would warrant; nearly every valuation model marks it far higher, from a Graham floor near $116 to relative and asset frames near $191 to $258.

The business is posting records, not declines: first-quarter 2026 EPS doubled to $3.86, net income rose 84%, collections hit a record $718 million, and management raised the 2026 collections target to $2.8 billion and EPS guidance to roughly $13, while the share count falls about 5% a year.

The discount is compensation for real risk: as a debt buyer its earnings rest on charge-off supply that moves with the consumer-credit cycle, the balance sheet carries net debt above 5x operating income with interest coverage of only about 2.3x, and recovery accounting depends on the company's own estimates of future collections.

Bull Case

The counterintuitive thing about Encore Capital is that it is posting record results and trading like a company in decline. First-quarter 2026 diluted EPS doubled to $3.86 from $1.93, net income jumped 84% to $86.2 million, revenue rose 21% to $475.4 million, and global collections hit a record $718.4 million, up nearly 19%. Yet the stock changes hands at about $82.97 (June 27, 2026), roughly 6.5x trailing EPS of $12.84 and a fraction of where almost every valuation model marks it. That is the metric that does not fit the obvious narrative: a business compounding collections at a record pace is being priced as if those collections will erode.

The model spread captures how wide the gap is. The relative P/E frame at a 12x sector multiple marks the stock near $191, the asset-based excess-return models land between $144 and $258, and the earnings-power value frame near $197. Inverting the price is even starker: at about 3x company-wide operating income, the market is paying below what even a 5% annual decline in operating profit would warrant. This is not a growth bet priced for perfection; it is a value name priced for deterioration that has not arrived. The current operating margin of 36.8% is roughly what the price implicitly assumes the business can hold, so a buyer is underwriting continuation, not improvement.

The operating engine behind the discount is strengthening, not weakening. Average receivable portfolios grew 14% to $4.4 billion, U.S. collections drove the record quarter, and management raised the 2026 collections target to $2.8 billion (up 8%) and guided full-year EPS to roughly $13, a 19% increase. The 10-Q describes the supplemental collections and portfolio data the business tracks (Q1 2026 10-Q, accession 0001084961-26-000009), and the company has been retiring shares, with the count down about 5% a year, so the per-share earnings power is rising on both higher profit and fewer shares. When a cheap stock is also buying itself back while earnings climb, the discount compounds in the holder's favor.

Bear Case

The right frame for a debt buyer is the cycle, and the bear case is that Encore is earning peak-looking profits off a supply tailwind that will not last. The business buys charged-off consumer receivables at a discount and collects more than it paid; its raw material is other people's defaults. Record collections and an 84% jump in net income are flattering precisely because the U.S. consumer-credit cycle has been generating abundant, attractively priced supply. When charge-off volumes normalize and competition for portfolios bids up purchase prices, the spread that produces a 36.8% operating margin compresses, and the earnings that look durable today reveal themselves as cyclical. The 10-Q already hints at the unevenness, noting that in its European markets default rates are generally low by historic levels and consumer lending volumes have stagnated (Q1 2026 10-Q, accession 0001084961-26-000009), which is the company telling you supply is not uniformly strong.

The balance sheet is the structural pressure point. Net debt sits near $3.8 billion against trailing operating income of about $681 million, a net-debt-to-operating-income ratio above 5x, and interest coverage is only about 2.3x. This is a heavily levered business by design, because buying portfolios requires funding, but leverage cuts both ways: rising rates raise the cost of the debt that funds the purchases, and the 10-Q warns that if new indebtedness is added to current levels the risks intensify and the company may not continue to satisfy its covenants (Q1 2026 10-Q, accession 0001084961-26-000009). A debt buyer that funds with debt is exposed at both ends of the rate cycle.

The accounting is genuinely hard to read, which is part of why the stock is cheap. Earnings depend on the company's own estimates of future recoveries on portfolios already bought; if those estimates prove optimistic, reported profit reverses through allowance charges. The free-cash-flow models in the X-ray break down here (they mark the stock near zero) because portfolio purchases, which are really the cost of goods, are treated as investing rather than operating, so headline cash flow understates the capital intensity. The high implied cost of capital in the valuation, near 18%, is the market's way of saying it does not fully trust the earning power. The deep discount is not free; it is compensation for cyclicality, leverage, and estimation risk.

Valuation

Encore screens as deeply cheap on almost every frame, and the question is whether the cheapness is opportunity or warning. The relative P/E model at a 12x sector multiple marks about $191, the simple excess-return model near $144, the two-stage excess-return model near $258, the earnings-power value frame near $197, and the residual-income model near $217. Against a $82.97 quote, the price sits well below all of them. The Graham number, a conservative floor, still lands near $116. The only models that mark near or below the price are the free-cash-flow capitalizations, and those are unreliable for a debt buyer because portfolio purchases (effectively the cost of inventory) are classified outside operating cash flow.

Inverting the price makes the discount concrete. At $82.97 the market pays about 3x company-wide operating income, a multiple so low that the price sits below what even a 5% annual operating-profit decline would warrant. Read this as a bound rather than a solved forecast: the market is not asking the business to grow, it is pricing in deterioration. The implied operating margin near 33.5% sits just below the current 36.8%, so the price embeds a slight erosion of profitability, not a collapse and not improvement.

The caveats temper the apparent bargain. The solve carries limited comparison data, so the label should be read directionally. More importantly, the business is levered (net debt above 5x operating income) and its earnings rest on estimates of future collections, which raises the genuine risk that today's profit is cyclically elevated. The honest summary: on reported numbers this is one of the cheaper names available, and the discount is the market demanding a high return for cyclicality, leverage, and the opacity of recovery accounting.

Catalysts

The most recent print was the first-quarter 2026 report, and it was strong enough to lift guidance. Diluted EPS doubled to $3.86 from $1.93, net income rose 84% to $86.2 million, revenue grew 21% to $475.4 million, and global collections set a record at $718.4 million, up nearly 19%, driven mainly by U.S. portfolios. Average receivable portfolios grew 14% to $4.4 billion, and global portfolio purchases were $363 million in the quarter.

Management raised the full-year outlook on the print: the 2026 collections target moved up to $2.8 billion (an 8% increase), full-year EPS is guided to roughly $13 (up 19%), and portfolio purchases are projected between $1.4 billion and $1.5 billion. The raised guidance is itself the near-term catalyst, and the next quarterly print is the test of whether collections momentum holds.

The forward thesis tracks two variables. The first is portfolio supply and pricing: the cleanest path to value is continued availability of charged-off receivables at attractive prices, which depends on the consumer-credit cycle. Watch U.S. charge-off trends and the prices Encore pays per portfolio, and note the company's observation that European default rates are low and lending volumes have stagnated, a softer supply signal there. The second is funding cost: as a levered buyer, Encore's profit is sensitive to interest expense, so watch the rate environment and the leverage ratio. A quarter that pairs continued collection strength with disciplined purchase pricing would support the value case; a quarter where purchase prices rise faster than collections, or funding costs climb, would validate the cyclical caution.

Sources: Encore Capital Q1 2026 results and 8-K (stocktitan.net, Globe and Mail); Encore Capital Q1 2026 earnings transcript (Motley Fool, AOL, Yahoo Finance); Q1 2026 10-Q (stocktitan.net).

Peer Cohorts (Per Segment, With Filing Citations)

Debt purchasing and recovery (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ECPG report on boothcheck